4.8 Article

Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial

Journal

LANCET
Volume 378, Issue 9801, Pages 1485-1492

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(11)61344-5

Keywords

-

Funding

  1. Sanofi-Aventis
  2. Coca Cola
  3. Allergan
  4. Roche products
  5. MSD
  6. GlaxoSmithKline
  7. Roche
  8. Tanita Medical Advisory Board
  9. Sara Lee
  10. Lilly
  11. Novartis
  12. Bristol-Myers Squibb
  13. iNova Pharmaceuticals
  14. Eisai Pharmaceuticals
  15. Pfizer Australia
  16. Servier Laboratories (Australia)
  17. Weight Watchers International
  18. MRC [MC_EX_G0800860, MC_U105960384, MC_U105960389] Funding Source: UKRI
  19. Medical Research Council [MC_EX_G0800860, MC_U105960389, MC_U105960384] Funding Source: researchfish

Ask authors/readers for more resources

Background The increasing prevalence of overweight and obesity needs effective approaches for weight loss in primary care and community settings. We compared weight loss with standard treatment in primary care with that achieved after referral by the primary care team to a commercial provider in the community. Methods In this parallel group, non-blinded, randomised controlled trial, 772 overweight and obese adults were recruited by primary care practices in Australia, Germany, and the UK. Participants were randomly assigned with a computer-generated simple randomisation sequence to receive either 12 months of standard care as defined by national treatment guidelines, or 12 months of free membership to a commercial programme (Weight Watchers), and followed up for 12 months. The primary outcome was weight change over 12 months. Analysis was by intention to treat (last observation carried forward [LOCF] and baseline observation carried forward [BOCF]) and in the population who completed the 12-month assessment. This trial is registered, number ISRCTN85485463. Findings 377 participants were assigned to the commercial programme, of whom 230 (61%) completed the 12-month assessment; and 395 were assigned to standard care, of whom 214 (54%) completed the 12-month assessment. In all analyses, participants in the commercial programme group lost twice as much weight as did those in the standard care group. Mean weight change at 12 months was -5.06 kg (SE 0.31) for those in the commercial programme versus -2.25 kg (0.21) for those receiving standard care (adjusted difference -2.77 kg, 95% CI -3.50 to -2.03) with LOCF; -4.06 kg (0.31) versus -1.77 kg (0.19; adjusted difference -2.29 kg, -2.99 to -1.58) with BOCF; and -6.65 kg (0.43) versus -3.26 kg (0.33; adjusted difference -3.16 kg, -4.23 to -2.11) for those who completed the 12-month assessment. Participants reported no adverse events related to trial participation. Interpretation Referral by a primary health-care professional to a commercial weight loss programme that provides regular weighing, advice about diet and physical activity, motivation, and group support can off er a clinically useful early intervention for weight management in overweight and obese people that can be delivered at large scale.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available